
17-r ANGI
16-r ANGI
15-r ANGI
14-r ANGI
13-r ANGI
12-r ANGI
11-r ANGI
10-r ANGI
9-r ANGI
8-r ANGI
7-r ANGI
6-r ANGI
5-r ANGI
4-r ANGI
3-r ANGI
2-r ANGI
1-r ANGI
MusclePharm Corp. announced plans to buy back $5 million of all common stock in December 2013. Repurchases under MusclePharm's new program will be made in open market or privately negotiated transactions in compliance with Rules 10b5-1 and 10b-18 under the Securities Exchange Act of 1934, subject to market conditions, applicable legal requirements, and other relevant factors. This share repurchase plan does not obligate the Company to acquire any particular amount of common stock, and it may be suspended at any time at the Company's discretion.In 2013 MusclePharm Corporation completed a $12 million registered direct offering of its Series D Convertible Preferred Stock.The Frost Group, LLC, headed by Miami entrepreneur, billionaire, Dr. Phillip Frost, was the lead investor in the offering and elected to increase its previously announced investment in the offering to a total of $2.9 million.
Post a Comment